Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Charles River Laboratories International Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $13.4B | |
|---|---|---|
| Revenue (ttm) | 4B | |
| Net income (ttm) | -238.5M | |
| EPS (ttm) | -$4.88 | |
| Shares out | 47.7M | |
| P/E (forward) | 22.5x | |
| Volume | 1,085,812 | |
| Beta | 1.40 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-25 | 2022-12-31 | 2023-12-30 | 2024-12-28 | 2025-12-27 | Trend |
| Revenue | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B | +3.2% |
| Gross profit | $1.33B | $1.46B | $1.50B | $1.33B | $1.23B | -2.1% |
| Operating income | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M | -54.6% |
| Net income | $391.0M | $486.2M | $474.6M | $22.2M | $-144.3M | — |
| EPS (diluted) | $7.60 | $9.48 | $9.22 | $0.20 | $-2.91 | — |
| EBITDA | $820.2M | $986.1M | $1.03B | $581.1M | $410.8M | -15.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $619.9M | $665.1M | $747.9M | $751.0M | $743.1M | +4.6% |
Recent company headlines from major financial publishers.
Under the base scenario, which carries a probability of 45.0%, biopharmaceutical preclinical study demand stabilizes following near-term budget austerity, and operational restructuring in Manufacturing Support eliminates segment operating losses. Normalized consolidated operating margins expand steadily toward peer benchmarks, driving the equity valuation to $367.67, representing an expected return of 32.2% relative to $278.06. This path is disconfirmed if early-stage biotechnology study cancellations accelerate or if fixed facility costs prevent margin expansion over the next several fiscal quarters.
In the bull scenario, assigned a probability of 25.0%, a decisive recovery in global biopharma venture funding spurs candidate progression into IND-enabling toxicology studies. Discovery and Safety Assessment study volume re-accelerates sharply, allowing substantial fixed-cost operating leverage to drive consolidated margins above peer benchmarks. Combined with a successful turnaround in Manufacturing Support and rapid debt repayment, equity value reaches Potential value of $459.24, delivering a return of 65.2% from $278.06. Investors would confirm this trajectory through sequential quarterly revenue growth re-acceleration and expanding backlog over the next year.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.9% | $142 | $142 | $142 | $142 | $142 |
| 8.9% | $137 | $137 | $137 | $137 | $137 |
| 9.9% | $131 | $131 | $131 | $131 | $131 |
| 10.9% | $126 | $126 | $126 | $126 | $126 |
| 11.9% | $122 | $122 | $122 | $122 | $122 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
